Clinical Trial Update: The FLOTILLA Study: Providing Continued Access to The Study Medicines Encorafenib and Binimetinib for Participants in Prior Clinical Trials [Phase 4]

View source ↗

Summary

The FLOTILLA Phase 4 trial update describes continued access to encorafenib and binimetinib for participants who previously enrolled in related studies.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• BRAFTOVI (ENCORAFENIB)
• MEKTOVI (BINIMETINIB)

Snippet

Sponsor: Pfizer | Conditions: Solid Tumors | Phase 4 | Status: RECRUITING